#JustReleased: AASTRO/ASCO/AUA 2018 guideline for prostate c
The American Society for Radiation Oncology (ASTRO), in collaboration with the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA), has recently released evidence-based clinical practice guideline on hypofractionated EBRT in localized prostate cancer. The guideline has been published in the Journal of Clinical Oncology.

The guidance document presents recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostate cancer.

The guidelines address 8 key questions on appropriate indications and dose-fractionation for moderately and ultrahypofractionated radiation therapy, as well as technical issues, including normal tissue dose constraints, treatment volumes, and use of image-guided and intensity modulated radiation therapy.

The key recommendations are:
• Based on high-quality evidence, strong consensus was reached for offering moderate hypofractionation across risk groups to patients choosing external beam radiation therapy

• The task force conditionally recommends ultrahypofractionated radiation may be offered for low- and intermediate-risk prostate cancer but strongly encourages treatment of intermediate-risk patients on a clinical trial or multi-institutional registry

• For high-risk patients, the task force conditionally recommends against routine use of ultrahypofractionated external beam radiation therapy

• With any hypofractionated approach, the task force strongly recommends image-guided radiation therapy and avoidance of nonmodulated 3-dimensional conformal techniques


Note: This list is a brief compilation of some of the key recommendations included in the guidelines and is not exhaustive and does not constitute medical advice. Kindly refer to the original publication here: http://ascopubs.org/doi/abs/10.1200/JCO.18.01097?af=R
D●●●a S●●●●●●j and 1 others like this
Like
Comment
Share